Bone regeneration achieved using mesenchymal stem cells (MSCs) and nonviral gene therapy holds great promise for patients with fractures seemingly unable to heal. Previously, MSCs overexpressing bone morphogenetic proteins (BMPs) were shown to differentiate into the osteogenic lineage and induce bone formation. In the present study, we evaluated the potential of osteogenic differentiation in porcine adipose tissue-and bone marrow-derived MSCs (ASCs and BMSCs, respectively) in vitro and in vivo when induced by nucleofection with rhBMP-2 or rhBMP-6. Our assessment of the in vivo efficiency of this procedure was made using quantitative micro-computed tomography (micro-CT). Nucleofection efficiency and cell viability were similar in both cell types; however, the micro-CT analyses demonstrated that in both ASCs and BMSCs, nucleofection with rhBMP-6 generated bone tissue faster and of higher volumes than nucleofection with rhBMP-2. RhBMP-6 induced more efficient osteogenic differentiation in vitro in BMSCs, and in fact, greater osteogenic potential was identified in BMSCs both in vitro and in vivo than in ASCs. On the basis of our findings, we conclude that BMSCs nucleofected with rhBMP-6 are superior at inducing bone formation in vivo than all other groups studied.
INTRODUCTION
Bone tissue is a specialized form of connective tissue that possesses a natural regenerative capacity. Nevertheless, 5-10% of all fractures and as many as 30% of patients with pre-existing conditions face impaired healing and significant morbidity, which in turn can also be economically burdensome. 1 To date, autologous bone grafting remains the 'gold standard' biological method used to promote nonunion fracture sites and spinal fusion in cases of intervertebral disc degeneration. 2, 3 However, failure rates as high as 30% have been cited together with complications resulting from repeated interventions. 1 Mesenchymal stem cells (MSCs) have been isolated from various adult tissues, among which are bone marrow (BM) and adipose tissue. MSCs have been shown to differentiate successfully into osteogenic, chondrogenic and adipogenic lineages. [4] [5] [6] In addition, when genetically modified, these multipotent cells have displayed the ability to form and regenerate bone in vivo in multiple animal models, providing gene-and cell-mediated therapy for clinical orthopedic applications. [7] [8] [9] [10] [11] The bone morphogenetic protein (BMP) family and its 20 identified members are regarded today as key signaling proteins responsible for organization of tissue architecture. 12 It is widely known that BMPs have an important role in osteogenesis. 1, 13 We previously showed that MSCs that have been genetically modified to overexpress BMP can produce regeneration in bone defects and form bone in vivo without the need for mass quantities of BMP proteins or harvested bone grafts. [7] [8] [9] [10] 14, 15 To date, a number of studies have been conducted to determine the most suitable BMP for osteogenic differentiation in vitro and in vivo. Most of these studies have been conducted with the aid of viral gene delivery. 1, [16] [17] [18] [19] [20] [21] Experiments involving MSCs infected with adenoviruses carrying 14 different human isoforms of BMP revealed that BMP-2, -6, and -9 are the most potent inducers of osteoblast differentiation in MSCs. 17, 21 BMP-2 and BMP-6 belong to two different subclasses, which were assigned based on similarities in amino acid sequences. 16 The use of BMP-2 in bone regeneration has been widely studied. As the FDA approved rhBMP-2 protein for clinical use in tibia and nonunion fractures, interest in this protein has become more widespread. 22 We previously showed that BMP-2 gene overexpression in MSCs induces bone formation and heals bone defects in vivo. 10, 15, [23] [24] [25] Although less popular, BMP-6 is also a prominent candidate for use in bone regeneration. Our studies have shown that BMP-6 is potent when used for osseous regeneration in bone defects and formation of bone in vivo. 8, 9, 26 Although viral gene delivery is more efficient than nonviral gene delivery, it poses several safety concerns. 27 In studies undertaken by us and others, nucleofection, a novel and efficient method for nonviral plasmid DNA delivery into MSCs, 28 has been used to overexpress rhBMP-2 and -6 in order to induce ectopic bone formation, 23 form spinal fusion, 9 and repair vertebral fractures. 8 Despite the use of nucleofection in numerous studies involving BMPs, the in vitro and in vivo efficiency of this process when used with various members of the BMP family in different types of adult stem cells has not yet been tested. Thus, our goal in the present study was to evaluate and compare the in vivo and 1 in vitro potentials of osteogenic differentiation in porcine adiposederived MSCs (ASCs) and BM-derived MSCs (BMSCs) induced by rhBMP-2 or rhBMP-6 via nucleofection.
We hypothesized that overexpression of rhBMP-2 and rhBMP-6 will have different effects on the osteogenic potentials of nucleofected ASCs and BMSCs in vivo and in vitro.
RESULTS

Nucleofection efficiency and cell viability
Porcine ASCs and BMSCs were nucleofected with pEGFP plasmid in order to determine the efficiency of nucleofection and compare it in the two cell types. Transfection efficiency was evaluated using flow cytometry and an analysis of green fluorescent protein (GFP)-positive cells among live cells. Nucleofected ASCs constituted 78.68± 4.76% and BMSCs 77.47±3.87% of GFP-positive cells; no statistically significant differences were found between the two groups (n ¼ 3, P40.05; Figure 1a ). Cell viability was determined as the percentage of live cells 24 h after nucleofection with rhBMP-2 or rhBMP-6; among the BMSCs there was 54% cell viability (n ¼ 5) following nucleofection with rhBMP-2 and 55% cell viability (n ¼ 5) after nucleofection with rhBMP-6. In the ASCs, there was 36% cell viability (n ¼ 3) following nucleofection with rhBMP-2 and 42% cell viability (n ¼ 3) after nucleofection with rhBMP-6. No statistically significant differences were found between rhBMP-2-and rhBMP-6-nucleofected cells, regardless of whether they were ASCs or BMSCs (P40.05, Figure 1b) .
In vitro evaluation of MSCs nucleofected with rhBMP-2 and rhBMP-6: RNA expression and protein secretion To evaluate the expression of transfected genes in ASCs and BMSCs that underwent nucleofection with rhBMP-2 (hereafter referred to as BMP2-ASCs and BMP2-BMSCs, respectively) or rhBMP-6 (hereafter referred to as BMP6-ASCs and BMP6-BMSCs, respectively), we used quantitative RT-PCR. Gene expression was assessed in ASCs and BMSCs 24 h after nucleofection. In both cell types, BMP-2 and BMP-6 genes were significantly elevated after nucleofection compared with control groups (non-nucleofected MSCs, hereafter referred to as control ASCs and control BMSCs). Both BMP2-ASCs and BMP2-BMSCs showed significantly higher gene expression than BMP6-ASCs and BMP6-BMSCs, respectively, although all four groups displayed the same level of magnitude of expression (n ¼ 5, Po0.05) (Figure 2a ).
An enzyme-linked immunosorbent assay (ELISA) was performed on media collected from cultures of nucleofected cells to compare the extent of secretion of genes overexpressed by these cells. Secretion of both rhBMP-2 and rhBMP-6 was significantly elevated after nucleofection: in BMP2-ASCs there was 2.96 ± 0.15 pg BMP-2 per ml per 24 h per ng protein (n ¼ 3), and in BMP2-BMSCs there was 3.47±0.29 pg BMP-2 per ml per 24 h per ng protein (n ¼ 3); there was no significant difference in secretion between the two cell types. Secretion of rhBMP-2 was 11 times higher in BMP2-ASCs and 30 times higher in BMP2-BMSCs than that found in respective control cells. When we tested BMP-6 secretion, we found that BMP6-BMSCs secreted 0.90±0.07 pg BMP-6 per ml per BMP-6 is more efficient in bone formation than BMP-2 O Mizrahi et al 24 h per ng protein (n ¼ 3) and BMP6-ASCs secreted 0.73 ± 0.19 pg BMP-6 per ml per 24 h per ng protein (n ¼ 3); again no statistical difference was evident between the two cell groups (n ¼ 3, P40.05). No rhBMP6 secretion was detected in any other experimental groups. Similar to the results of the RNA expression analysis, rhBMP-6 secretion was significantly lower than rhBMP-2 secretion in both cell types (Figures 2b and c) .
In vitro osteogenic potential of MSCs nucleofected with rhBMP-2 or rhBMP-6 In vitro induction of osteogenic differentiation was performed to compare the osteogenic potentials of nucleofected cells. ASCs and BMSCs nucleofected with rhBMP-2 or rhBMP-6 were cultured in osteogenic maintenance media for 7 days. A quantitative alkaline phosphatase (ALP) colorimetric assay was performed to evaluate cell differentiation. All cells transfected with rhBMP-2 or rhBMP-6 successfully differentiated into the osteogenic lineage and displayed significantly higher ALP activity than respective control cells. BMP6-BMSCs displayed significantly higher ALP activity than BMP2-BMSCs (4.70 ± 0.11 vs 3.99 ± 0.04 ALP activity per min per ml per ng protein, respectively, n ¼ 5, Po0.05). Transfected with either BMP-2 or BMP-6, ASCs exhibited significantly lower levels of ALP activity than BMSCs nucleofected with the same plasmid. In the BMP2-ASCs, there was 1.23 ± 0.14 ALP activity per min per ml per ng protein, whereas in the BMP6-ASCs, there was 1.05 ± 0.20 ALP activity per min per ml per ng protein (n ¼ 5, Po0.05). Among the ASC groups, there was no difference in ALP activity of cells nucleofected with BMP-2 (BMP2-ASCs) or BMP-6 ( Figure 3a) . To evaluate calcium deposition in differentiating cells, we performed Von Kossa staining in vitro. Positive staining was identified in all cells nucleofected with rhBMP-2 or rhBMP-6, although staining was weaker in ASCs. No Von Kossa staining was evident in the control cell groups (Figure 3b ).
In vivo evaluation of bone formation: micro-CT analysis Porcine ASCs and BMSCs genetically engineered to overexpress rhBMP-2 or rhBMP-6 were injected into the thigh muscles of NOD/ SCID mice to evaluate different cells' ability to form bone in vivo. Micro-CT analysis was used to evaluate ectopic bone formation (Figures 4 and 5) . Bone formation was successfully detected in all groups of genetically modified cells. BMP2-ASCs were the only cells in which bone formation was not observed in all mice (four of eight). Quantitative micro-CT analysis was performed to evaluate new bone structural indexes. In the ASC groups, the parameters examined in BMP6-ASCs were superior to those in BMP2-ASCs. Bone volume (BV) was significantly higher in BMP6-ASCs as early as week 2: 19.53 ± 10.07 mm 3 (n ¼ 8, Po0.05) compared with 1.57 ± 1.1507 mm 3 (n ¼ 8) in BMP2-ASCs. This trend continued through week 4 (12.85±2.73 mm 3 in BMP6-ASCs vs 2.10±0.94 mm 3 in BMP2-ASCs; n ¼ 8) and week 6 (9.28± 1.85 mm 3 in BMP6-ASCs vs 1.14 ± 1.85 mm 3 in BMP2-ASCs; n ¼ 8) (Figure 5a ). Interestingly, there was a decrease in average BV over time in both ASC groups (Figure 5a ), although the bone mineral density (BMD) values were similar in the two groups. All groups displayed increasing BMD over time ( Figure 5b ). BMSCs genetically engineered to overexpress rhBMP-6 demonstrated significantly higher BVs than BMSCs engineered to overexpress rhBMP-2 at 2 weeks: 33.42 ± 4.86 mm 3 and 10.86 ± 2.78 mm 3 , respectively (n ¼ 5, Po0.05). BMP2-BMSCs exhibited an increase in BV up to 4 weeks; from that point onward BV was similar in the two groups. BMD steadily increased over time whereas remaining similar in BMP2-BMSCs and BMP6-BMSCs throughout the various 
DISCUSSION
ASCs and BMSCs are prominent candidates for future clinical applications in tissue regeneration and, particularly, in bone repair. 11, 27, 29 We compared the in vitro and in vivo osteogenic potentials of ASCs and BMSCs that had been nonvirally transfected with either rhBMP-2 or rhBMP-6 using nucleofection. The goal of this study was to determine the most suitable setting for developing cell and gene therapy for bone regeneration. We previously studied both cell populations and their genetic modifications with rhBMP-2 or rhBMP-6 to induce ectopic bone and repair bone defects. 8, 23, 26 In the present study, our goal was to compare the four cell and gene combinations so that we could determine, which is the most efficient for de novo bone tissue formation and, thus, the most efficient for bone tissue regeneration therapies.
Our results demonstrate that BMP-6 is more efficient in bone tissue formation than BMP-2 when overexpressed in ASCs and BMSCs. In addition, BMP-6 is more efficient than BMP-2 in inducing osteogenic differentiation in vitro in BMSCs. Compared with ASCs, BMSCs have greater osteogenic potential both in vitro and in vivo. We also found that although ASCs and BMSCs have different origins, there was no difference in nucleofection efficiency, cell viability after nucleofection or BMP secretion between the cell types, even if transgene expression differed.
Both ASCs and BMSCs nucleofected with rhBMP-2 or rhBMP-6 were able to induce bone formation in vivo. BMP6-ASCs exhibited significantly superior BV values at all time points when compared with BMP2-ASCs, and BMP6-BMSCs achieved significantly higher BV values than BMP2-BMSCs at the 2-week time point. These results indicate that rhBMP-6 induced a more robust osteogenesis in ASCs and promoted faster bone formation in BMSCs. 
Osteogenic potentials of different BMPs have been tested previously, although to date no study has involved a comparison between various BMPs when nonvirally delivered to MSCs. There are studies supporting our finding that BMP-6 has a greater osteogenic potential in vivo.
13,17,20 Luu 17 and Li 20 as well as their colleagues showed that cell lines infected with adeno-BMP-6 and implanted in ectopic sites in mice and rats induced more bone than cells infected with adeno-BMP-2. Furthermore, when these cells were implanted in immunocompetent rats, no bone formation was seen in animals treated with adeno-BMP-2. In the C2Cl12 cell line (a mouse myoblast cell line), researchers found that cells infected with the adeno-BMP-6 viral vector and injected ectopically in the thigh muscle of mice produced bone formation earlier than cells infected with adeno-BMP-2. 13 When testing indexes of newly formed bone, a decrease in BV is visible at week 2 or 4 in the BMP-6-treated groups. This phenomenon, which is often seen in ectopic bone models (our personal observations), is most probably due to partial resorption of ectopic bone. In the present study, BMD values were similar among the different groups and significantly increased over time, indicating that the quality of bone was similar in all experimental groups. The clear differences between experimental groups were the timing of the first visible bone formation (2 weeks post nucleofection in BMP-6-overexpressing cells) and BV. This study was performed in an ectopic site; we believe that using these settings in orthotopic site will result in further increased bone formation similar to that formed when genetically manipulated MSCs were implanted into the segmental defect site as previously reviewed, 7, 30, 31 or similar to the fracture repair seen when porcine ASCs nucleofected with BMP-6 were implanted into fractured vertebrae. 8 Similar to the in vivo results, BMP6-BMSCs exhibited an in vitro osteogenic induction capacity that was superior to that of BMP2-BMSCs. Authors of numerous studies have reported BMP-6's superiority over BMP-2 in inducing osteogenic differentiation in vitro. 16, 17, 20 Interestingly, we did not see the same phenomenon in the ASCs group, in which there were no statistical difference between BMP-2 and BMP-6 nucleofected cells. This is most probably due to relatively low osteogenic differentiation potential of ASCs in vitro and low sensitivity of the differentiation assay.
No statistical difference in nucleofection efficiency or cell viability was found between the two cell types, indicating that both cell types respond equally to the nucleofection parameters and thus share similar cell properties. Nonetheless, cell viability after nucleofection in both cell types was relatively low when compared with viral delivery methods, 27 with 50 and 35% viable cells among BMSCs and ASCs, respectively. Indeed, nucleofection posses limitation with regards to cell viability and efficiency, however these limitation can be overcome with performing the genetic manipulation ex-vivo, which enables to control cell numbers. An RNA expression analysis and an ELISA for protein secretion, performed 24 h after nucleofection, showed significantly high expression and secretion of BMP-2 in both cell types. Although BMP-2 expression was higher than BMP-6, being this finding probably due to the fact that there is baseline secretion of BMP-2 in MSCs, BMP-6-transfected cells showed higher bone formation ability, suggesting that rhBMP-6 truly is more potent in inducing osteogenic differentiation. 32, 33 An ELISA for rhBMP-6 secretion yielded positive findings only in groups nucleofected with the rhBMP-6 plasmid; the other cell groups did not exhibit any baseline secretion of the protein. It is possible that the detected amounts of BMP-6 mRNA were insufficient to initiate BMP-6 secretion at detectable levels. Alternatively, there may be a BMP-6 is more efficient in bone formation than BMP-2 O Mizrahi et al control system on the translation level that downregulates BMP-6 in baseline conditions. We also compared the osteogenic potentials of ASCs and BMSCs in vitro and in vivo. Genetically modified BMSCs were significantly superior to genetically modified ASCs in in vivo bone formation, with a higher BV and more robust osteogenic differentiation in vitro. Many studies have been conducted to compare the differentiation potential of these two cell populations. 34, 35 Clearly both cell types differ from each other in their differentiation capacities based on an RNA expression analysis of differentiation-related genes. 35, 36 Two studies support our findings and quantitatively show that BMSCs possess a superior osteogenic potential in vitro. 37, 38 The majority of other studies showing that both cell types have similar osteogenic potential did not include a qualitative analysis. [39] [40] [41] As for the cells' osteogenic potential in vivo, very few studies have been conducted to date: BMSCs seeded on ceramic scaffolds were shown to be superior to ASCs in inducing bone formation in a sheep critical-size tibia defect, 42 and rat BMSCs and composites of hydroxyapatite ceramics seeded subcutaneously produced higher BVs than ASCs implanted in the same manner. 37 Nevertheless, our goal in the present study was to evaluate differences in the osteogenic potentials of both cell populations in the setting of a nonviral approach and to estimate the impact of these differences on the cells' differentiation potentials.
There are a few proposed mechanisms that can explain BMP-6's superiority over BMP-2 in inducing osteogenic differentiation. Several studies have determined that as BMP-2 and BMP-6 belong to a different subclass of the BMP family, they work through different signal transduction pathways. 12, 20, 43 It is well known that BMP activities are mediated by tetramers of serine/threonine kinase receptors, which consist of two type I and two type II receptors. Lavery et al. 12 showed in primary MSCs that the degree of reliance on receptors varies between members of the two BMP subclasses; these findings can indicate that BMP-2 and BMP-6 work through different mechanisms when inducing osteogenic differentiation. In addition, Jane et al. 43 studied bone formation using ectopic injection of adenoviruses that express different BMPs into rat limbs. Those researchers concluded that adeno-BMP-6 induced bone formation via a mechanism that differed from that of adeno-BMP-2 and -4. They suggest that BMP-6 forms bone through a mechanism similar to both osteochondral and intramembranous ossification pathways with MSC recruitments and proliferation, however, the membranous path being the primary one and thus resulted in more rapid calcification. In our study, we did not see any morphological difference between the two newly formed tissues. However, direct gene delivery relies exclusively on host cells, whereas our gene and cell therapy approach combines the donor MSC contribution and host response to secreted BMP, which together results in more efficient and different tissue formation.
In another aspect, Vukicevic et al. 33 suggested that BMP-6 is secreted from osteoclasts and serves as a key factor that couples bone remodeling with recruitment of osteoblasts to the site, thus increasing bone formation. This notion is supported by another report showing that systemic administration of BMP-6 to ovariectomized rats reduced bone resorption and increased bone growth, resulting in cumulative bone formation. 44 Genetic modification is a powerful method to control the fate of MSCs. Recently, nonviral gene delivery systems have become more attractive to researchers because of their relative safety in allowing transient overexpression of therapeutic genes. However, experience with these techniques is still limited, and standardization and optimization of existent protocols are necessary. To our knowledge, this is the first study in which researchers methodically compared the osteogenic potential of MSCs nonvirally transduced to overexpress different BMPs. We can conclude that rhBMP-6 is more potent in inducing rapid bone formation in genetically modified MSCs. Although BMP-2 has decades of research and clinical use behind it, compared with BMP-6, BMP-2 has been shown to cause adverse side-effects. [45] [46] [47] We therefore strongly believe that future gene and stem cell therapies for bone fractures, osteoporosis and spinal disorders will be more efficient if BMP-6 is used. In the present study, we also demonstrated that the osteogenic potentials of BMSCs in vitro and in vivo are significantly superior to those of ASCs. Although ASCs can still be used in bone tissue engineering because of their higher availability, one should keep in mind that the BMSCs are more potent, and in cases in which rapid regeneration is critical or the amount of cells that can be used is limited, BMSCs should be the preferred choice.
MATERIALS AND METHODS Materials
All materials were supplied by Sigma Aldrich (St Louis, MO, USA) unless otherwise stated.
MSC isolation and culture
The Institutional Animal Care and Use Committee of Cedars-Sinai Medical Center approved all animal studies described in this paper. MSCs were isolated as previously described from costal BM and the subcutaneous adipose tissues of euthanized pigs (weighing 35-40 kg with an average age of 1.5 years). 9, 23, 48 Briefly, adipose tissues and costal BM were harvested aseptically. The adipose tissues were cut into small pieces (5 mm Â 5 mm or less), washed with 1% BSA PBS (Invitrogen, Carlsbad, CA, USA), and treated with 0.075% collagenase at 37 1C for 1 h. The BM-containing ribs were scraped, flushed with PBS, and centrifuged at 900g for 10 min. The pellet was resuspended in PBS, after which it was layered on lymphocyte separation medium (ICN Pharmaceuticals, Bryan, OH, USA) and centrifuged at 900g for 30 min at 30 1C without a break. At the end of the isolation process, the isolated mononuclear cells from both tissues were plated in tissue-culture dishes at a density of 0.4 Â 10 6 cells per cm 2 in 5% CO 2 /95% air at 37 1C. The culture medium, which consisted of high-glucose Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 2 mM L-glutamine, 100 U ml À 1 penicillin/streptomycin (Invitrogen), and 10% fetal calf serum (Invitrogen), was changed first after 72 h and thereafter every 3-4 days. On confluence, the cells were trypsinized using 0.25% trypsin-EDTA (Invitrogen) and replated at a density of 7 Â 10 4 cells per cm 2 for expansion. Cells were grown in culture up to the fifth passage and used for in vitro and in vivo differentiation.
Efficiency of nucleofection in MSCs
Nucleofection was performed with the aid of a Nucleofector device (Amaxa Biosystems, Cologne, Germany) and an MSC-specific nucleofection buffer. As previously described, 2 Â 10 6 porcine ASCs or BMSCs were transfected with 10 mg plasmid. 8, 26 The reporter vector pCMV-EGFP-N1 (Clontech, Mountain View, CA, USA; hereafter referred to as pEGFP), which encodes the enhanced GFP gene, was used to evaluate nucleofection efficiency. To induce bone formation, ASCs or BMSCs were nucleofected with pNGVL1-pCMVrhBMP-2 (rhBMP-2) or cDNA3-pCMV-rhBMP-6 (rhBMP-6). The nucleofection procedure was performed using program G22, which we found to be optimal in our previously reported studies. 9, 23 Immediately after nucleofection, the cells were placed in complete growth medium (including 20% fetal calf serum) and maintained in culture for 24 h. Viable cells were counted after Trypan blue staining by using the Countess Automated Cell Counter. Cell viability was calculated as the ratio of surviving cells to initially nucleofected cells, as previously reported. 
Gene expression analysis
A quantitative RT-PCR was conducted to estimate the levels of BMP-2 and BMP-6 gene expression in the nucleofected cells. The cells were trypsinized 24 h after nucleofection, counted and placed in aliquots (n ¼ 5 for each nucleofected cell type, n ¼ 4 for control cells). Total RNA was extracted from the cells using TRIzol reagent and retrotranscribed using random primers and reverse transcriptase (Promega Corp., Madison, WI, USA). Expression of BMP-2 and BMP-6 genes was analyzed using the ABI7500 Prism system (Applied Biosystems, Foster City, CA, USA) according to an absolute quantification method based on the standard curve of known plasmid quantities and Assay-on-Demand gene-expression assays (Applied Biosystems Hs00154192_m1 and Hs00233470_m1, respectively).
In vitro protein secretion assay ELISAs (R&D Systems, Minneapolis, MN, USA) were performed to measure the amount of rhBMP-2 or rhBMP-6 secreted by the cells after nucleofection. For this purpose, we reseeded the cells 24 h after nucleofection and collected culture media from the various experimental MSC groups 48 h after nucleofection. Control samples of non-nucleofected cells were used as well. This procedure was conducted according to the supplier's protocol (n ¼ 3).
Osteogenic differentiation in vitro
To assess the in vitro osteogenic potential of porcine ASCs and BMSCs overexpressing rhBMP-2 or rhBMP-6, we plated nucleofected cells at a density of 7.5 Â 10 4 cells per cm 2 in maintenance media consisting of culture medium containing 0.05 mM ascorbic acid-2-phosphate and 10 mM b-glycerophosphate. Non-nucleofected cells grown in maintenance medium served as a negative control. After 7 days, the cells were harvested for ALP and Von Kossa staining. An ALP colorimetric assay was performed in a manner previously described 10 (n ¼ 5 for each nucleofected cell type, n ¼ 3 for control cells). Values were normalized for protein content, which was measured by performing a bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA). Von Kossa staining was performed to evaluate calcium deposition in the differentiated cells. The cells were washed with PBS, fixed in cold 10% formaldehyde, rinsed with distilled water and then immersed in 2% silver nitrate solution. Following this, the cells were exposed to bright light for 15 min. Culture plates were counterstained with 0.1% Safranin-O for 5 min in room temperature. Mineralization was captured by a light microscope.
Surgical procedures
The MSCs were nucleofected, as described earlier, 24 h before cell injection. For the purposes of cell detection, injected cells were labeled with Vibrant-CM-DiI (Invitrogen) in accordance with previously described protocols. 9 To evaluate the in vivo osteogenic potential of these cells following nucleofection, we first anesthetized immunodeficient mice (NOD/SCID) via an intraperitoneal injection of a xylazine-ketamine mixture. 49 We resuspended 5 Â 10 6 nucleofected porcine MSCs in 50 ml of fibrin gel (Tisseel kit; Baxter, Vienna, Austria) and injected the solution into the thigh muscles of the animals. Each mouse received one injection of MSCs (either ASCs or BMSCs) that had been nucleofected with rhBMP-2 in its right hind limb and another injection of MSCs that had been nucleofected with rhBMP-6 in its left hind limb. Bone formation was monitored every 2 weeks for 6 weeks. At the end of this period, the mice were euthanized and their limbs were harvested for histological analysis.
Analysis of bone formation in vivo using micro-computed tomography
In vivo bone formation was evaluated over time by performing micro-CT analyses. All micro-CT procedures used in this study were previously described in detail by Kallai et al. 50 The mice underwent in vivo micro-CT scanning while anesthetized on weeks 2, 4 and 6 following cell implantation; we used a preclinical cone-beam in vivo micro-CT system (vivaCT 40; Scanco Medical AG, Bruttisellen, Switzerland). Microtomographic slices were acquired using an X-ray tube potential of 55 kVp and reconstructed at a spatial nominal resolution of 35 mm. A constrained three-dimensional (3D) Gaussian filter (s ¼ 0.8 and support ¼ 1) was used to partly suppress the noise found in the volumes. The bone was segmented from BM and soft tissue by using a global thresholding procedure. 51 Newly formed bone was separated from the animal's radius and tibia by applying a manual contouring method. BV, which represented the volume of mineralized tissue, and BMD, which was based on standardization of scans of hydroxyapatite samples, were determined for newly formed bone on the basis of microtomographic data sets by using direct 3D morphometry. 52 
Histological analysis
The harvested limbs were fixed in 4% formalin, decalcified using 0.5 M EDTA solution (pH 7.4), dehydrated and embedded in paraffin. Bone matrix-specific Masson's trichrome staining was performed on the paraffinembedded sections in a manner previously reported. 8, 9 Slides containing cells labeled with CM-DiI were counterstained with DAPI (4 0 ,6-diamidino-2-phenylindole) for 5 min, then mounted using GVA Mounting Solution (Invitrogen). CM-DiI and DAPI were captured using fluorescent microscopy.
Statistical analysis
All mean values in the Results section and in figures are displayed with their standard errors (s.e.). ANOVA models were constructed to analyze differences in the averages of RNA expression variables, ELISAs and ALP activity between groups. Where significant, pair-wise comparisons between groups and types were tested using post hoc Tukey-Kramer adjusted t-tests. T-tests were used to analyze differences across RNA expression variables between different groups, such as a comparison of BMP-2 expression in BMP2-ASCs and BMP6 expression in BMP6-ASCs. To analyze the effects of cell type, cell group and time on in vivo micro-CT parameters, a linear mixed model was used for each outcome. An autoregressive correlation structure was used in which each mouse leg was treated as the experimental unit. Random intercepts were fit for each mouse in all models. For the denominator degrees of freedom we used a Kenward-Roger adjustment for the tests in the model. Where significant, pair-wise tests of effects in the models included Tukey-Kramer adjustments for multiplicity. The minimal criterion for significance was determined to be a probability level o0.05.
